![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 2.75% | 28.00 | 27.60 | 28.00 | 27.80 | 27.25 | 27.25 | 2,193,935 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.73 | 185.4M |
TIDMRVG
Retroscreen Virology Group PLC
19 March 2014
For immediate release 07.00: 19 March 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
NEW STATE OF THE ART BIOMEDICAL FACILITY IN UK
Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "virometrics" specialist, is pleased to announce that it has signed a long term lease on a facility at the Chesterford Research Park in the UK with the plan to create a state of the art biomedical facility. This new bespoke facility will allow the further development and commercial exploitation of the Company's viral challenge technology platform.
Located at Little Chesterford in North Essex, the 42,000 square foot facility will house a quarantine unit, containing 40 ensuite isolation beds, together with a separate suite of laboratories for the Company's bioanalytical work. The facility, which is targeted to be fully operational in early 2015, will dramatically improve and broaden the Company's operational capability. In particular, this planned expansion will allow the Company both to conduct clinical studies for its clients and to leverage its new viral challenge models for commercial and research purposes.
Kym Denny, Chief Executive Officer, commented, "Retroscreen is actively broadening its capabilities and this new bespoke facility at Chesterford will allow us to undertake bedside to bench biomedical research all on one site. This exciting development follows the successful inoculation of our 1,500(th) volunteer which was achieved in just over a year since reaching the landmark of our 1,000(th) volunteer inoculation on 10 December 2012. This is a testament to the industry's adoption of our viral challenge models and our client delivery."
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGRGDXXGBBGSC
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions